01—Abstract
Summary
Summary of the 10-Q filed August 1, 2024. Cited figures are marked; the original filing is the authoritative source.
BridgeBio Pharma, Inc. ("BridgeBio") reported a net loss of $111.7 milliona for the six months ended June 30, 2024, compared with $303.4 million in the same period of 2023, and a net loss of $75.5 million for the three months ended June 30, 2024.
Six-month revenue was $213.3 millionb, up from $3.5 million a year earlier, driven mainly by $202.9 million recognized from the upfront license fees and services revenue under the Bayer Agreement and the KKC Agreement. Research and development expense rose to $255.7 million for the six months and selling, general and administrative expense rose to $125.3 million, reflecting commercialization readiness efforts. The three-month period also included a $126.3 million non-cash gain from deconsolidating TheRas, Inc. (BridgeBio Oncology Therapeutics), following its $200.0 million private equity financing in which BridgeBio's ownership fell to approximately 37.9%.
At June 30, 2024, cash, cash equivalents and marketable securities totaled $447.8 millionc, with restricted cash of $139.4 million, largely escrowed under the Financing Agreement from asset sale proceeds. Total debt principal included $747.5 million of 2029 Notes, $550.0 million of 2027 Notes and a $450.0 million term loan under the Amended Financing Agreement, which was used to repay the prior term loan in January 2024. Stockholders' deficit improved to $1.08 billion from $1.34 billion at December 31, 2023, following public offerings that raised $314.8 million in net proceeds during the first half of 2024.
The company stated that its cash and equivalents should fund operations for at least the next 12 months. A pending Funding Agreement would provide $500.0 milliond upon the first FDA approval of acoramidis, which had been submitted to the FDA on December 5, 2023.
02—Key points
Key Highlights
- Six-month 2024 revenue of $213.3 million versus $3.5 million in 2023, mainly from the Bayer and Kyowa Kirin license agreements.
- Net loss narrowed to $111.7 million for the six months ended June 30, 2024, from $303.4 million a year earlier; the quarter's net loss was $75.5 million.
- $126.3 million gain on deconsolidation of TheRas, Inc. (BBOT) in the second quarter; retained 37.9% stake carried at $117.0 million as an equity method investment.
- Cash, cash equivalents and marketable securities of $447.8 million plus $139.4 million of restricted cash at June 30, 2024.
- Debt refinanced in January 2024: $450.0 million term loan under the Financing Agreement replaced the Amended Loan Agreement, with a $26.6 million loss on extinguishment.
- $314.8 million in net proceeds from common stock public offerings in the first half of 2024.
- Pending $500.0 million Funding Agreement payable on first FDA approval of acoramidis, with a May 15, 2025 outside date.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2024filed August 1, 2024Financial Statements
Q2 FY2024 against Q2 FY2023
| Line item | Q2 FY2024Q2 FY2023 | Change |
|---|---|---|
| Revenue | $2.17M$1.64M | +32.1% |
| Cost of Revenue | $598K$599K | −0.2% |
| Gross Profit | $1.57M$1.04M | +50.7% |
| R&D Expenses | $114.69M$107.49M | +6.7% |
| SG&A Expenses | $59.52M$36.12M | +64.8% |
| Operating Expenses | $177.71M$147.74M | +20.3% |
| Operating Income | -$175.54M-$146.10M | −20.2% |
| Interest Expense | $8.58M$8.55M | +0.3% |
| Net Income | -$73.46M-$157.90M | +53.5% |
| EPS (Basic) | $-0.39$-0.98 | +60.2% |
| EPS (Diluted) | $-0.39$-0.98 | +60.2% |
| Shares Outstanding (Basic) | 187.59M160.54M | +16.9% |
| Shares Outstanding (Diluted) | 187.59M160.54M | +16.9% |
05—Questions
Frequently Asked Questions
Why did revenue increase so significantly in the first half of 2024?
Revenue was $213.3 million for the six months ended June 30, 2024, compared with $3.5 million a year earlier. The filing attributes the increase mainly to $202.9 million from recognizing the upfront license fee and services revenue under the Bayer Agreement ($135.0 million upfront) and the KKC Agreement ($100.0 million upfront).
How did the TheRas/BBOT transaction affect reported results?
On April 30, 2024, TheRas completed a $200.0 million private equity financing that reduced BridgeBio's ownership to approximately 37.9%. BridgeBio deconsolidated the entity and recognized a $126.3 million net gain, while recording a $7.9 million net loss from its equity method investment for May and June 2024.
What are the company's main debt obligations and how is cash restricted?
Debt principal at June 30, 2024 included $747.5 million of 2029 Notes, $550.0 million of 2027 Notes and a $450.0 million term loan. Under the Amended Financing Agreement, 75% of net proceeds from certain asset sales must be escrowed; $139.3 million remained in escrow as restricted cash, and a minimum unrestricted qualified cash balance of $78.0 million applied as of June 30, 2024.
What is the Funding Agreement and what are its conditions?
The Funding Agreement, entered January 17, 2024, provides for the Purchasers to pay $500.0 million (net of certain transaction expenses) upon the first FDA approval of acoramidis, in exchange for royalty payments of 5% of global net sales, subject to a $950.0 million cap. As of June 30, 2024, no proceeds had been received, and either party may terminate if the funding date does not occur by May 15, 2025.
Does the company have enough cash to fund operations?
The company stated that its cash, cash equivalents, marketable securities and restricted cash are expected to fund operations for at least the next 12 months from the filing date, based on current operating plans. It also noted it may need additional funding sooner if plans change, and that it expects to continue incurring significant operating and net losses over the next several years.
06—Continue